Enhancing sensitivity of triple-negative breast cancer to DNA-damaging therapy through chemical inhibition of the m6A methyltransferase METTL3

Cancer Commun (Lond). 2024 Feb;44(2):282-286. doi: 10.1002/cac2.12509. Epub 2023 Dec 15.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenine / analogs & derivatives*
  • DNA
  • Humans
  • Methyltransferases / genetics
  • Triple Negative Breast Neoplasms* / drug therapy

Substances

  • 6-methyladenine
  • Methyltransferases
  • DNA
  • METTL3 protein, human
  • Adenine